The antiviral benefit of antibodies can be compromised by viral escape especially for rapidly
evolving viruses. Therefore, durable, effective antibodies must be both broad and potent to …

Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain …

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody
neutralization response and its evasion by emerging viral variants and variant of concern …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

The emergence of highly transmissible SARS-CoV-2 variants of concern (VOC) that are
resistant to therapeutic antibodies highlights the need for continuing discovery of broadly …

INTRODUCTION Worldwide appearance of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) variants of concern (VOCs) with increased transmissibility and resistance to …

Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and are a major contributor to neutralizing antibody responses …

Prevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …

Monoclonal antibodies targeting a variety of epitopes have been isolated from individuals
previously infected with SARS-CoV-2, but the relative contributions of these different …

Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …